Medications

Therapy for rare bone disorder shows promise in clinical trial

A clinical trial at the National Institutes of Health found that a medication, denosumab, significantly reduced abnormal bone turnover in adults with fibrous dysplasia, a rare disease marked by weak and misshapen bones. Bone ...

Gerontology & Geriatrics

Osteoporosis drug prescribing often does not follow guidelines

Less than one in 10 commercially insured patients in the United States who broke a hip, a major complication of osteoporosis, receive any osteoporosis medical treatment within two calendar quarters of their fracture, according ...

Medications

Vertebral fractures up with long-term delay of denosumab

(HealthDay)—Compared with on-time dosing, delay of denosumab by more than 16 weeks is associated with an increased risk for vertebral fractures, according to a study published online July 28 in the Annals of Internal Medicine.

Diseases, Conditions, Syndromes

Confusion about long-term treatment of osteoporosis clarified

Osteoporosis is a common disorder among postmenopausal women which results in an increased risk of fractures. While several therapies improve bone strength and reduce the risk of spine and hip fracture, there is no cure for ...

Diseases, Conditions, Syndromes

Osteoporosis drugs compared for side effects, efficacy

A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic ...

Medications

Xgeva approved for rare, non-malignant tumor

(HealthDay)—Xgeva (denosumab) has been approved by the U.S. Food and Drug Administration to treat giant cell tumor of the bone (GCTB), a rare tumor that's most often non-cancerous.

page 1 from 2